CSPG4 通过调控 TGF-β 信号增强 RDEB 相关皮肤鳞癌侵袭
该研究探讨 CSPG4 在隐性营养不良性大疱性表皮松解症(RDEB)相关皮肤鳞状细胞癌(cSCC)中的表达与功能。体外实验显示抑制 CSPG4 可降低 RDEB cSCC 细胞系侵袭潜力,并改变 TGF-β1 刺激下 SMAD3 磷酸化;体内瘤组织及已发表 scRNA-Seq 数据提示 CSPG4 定位于肿瘤-间质界面,与 EMT 转录特征相关。结论提示 CSPG4 可能成为 RDEB cSCC 的治疗靶点。
要点
- 抑制 CSPG4 可降低 RDEB cSCC 细胞系侵袭潜力。
- CSPG4 定位于 RDEB cSCC 肿瘤侵袭前沿及纤维化 RDEB 皮肤基底层层角质形成细胞。
- CSPG4 可能通过 SMAD3 增强膜近端 TGF-β 信号,促进 EMT。
核心结论
- CSPG4 在 RDEB cSCC 细胞系中增强肿瘤侵袭潜力,机制涉及增强膜近端 TGF-β 刺激经 SMAD3 的信号激活,而 SMAD3 是 RDEB cSCC 中 EMT 的关键介质。
- CSPG4 可能作为 RDEB cSCC 临床管理的治疗靶点。
研究设计与样本
- 使用 RDEB cSCC 细胞系评估 CSPG4 依赖的侵袭潜力、TGF-β1 刺激信号激活及体外全层肿瘤模型中的细胞病理学指标变化。
- 通过免疫组化分析 RDEB cSCC 肿瘤中 CSPG4 表达,并利用已发表单细胞 RNA 测序(scRNA-Seq)数据分析非 RDEB cSCC 肿瘤中 CSPG4 表达。
主要发现
- 抑制 CSPG4 表达降低多个 RDEB cSCC 细胞系的侵袭潜力。
- 抑制 CSPG4 表达通过改变 SMAD3 磷酸化而改变膜近端 TGF-β 信号激活。
- CSPG4 表达在体内纤维化 RDEB 皮肤中均匀定位于基底层层角质形成细胞,在 RDEB cSCC 肿瘤中定位于侵袭前沿的肿瘤-间质界面肿瘤细胞。
- 已发表 scRNA-Seq 数据显示非 RDEB cSCC 肿瘤-间质界面细胞中 CSPG4 表达与增强的 EMT 转录组特征相关。
- 体外肿瘤模型中,细胞病理学指标(如核:细胞面积比)受 CSPG4 表达影响。
临床怎么用
- CSPG4 可能作为 RDEB cSCC 的潜在治疗靶点,靶向该蛋白或可限制 RDEB 相关皮肤癌的侵袭和转移。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic skin-blistering disorder that often progresses to metastatic cutaneous squamous cell carcinoma (cSCC) at chronic wound sites. Chondroitin sulfate proteoglycan 4 (CSPG4) is a cell-surface proteoglycan that is an oncoantigen in multiple malignancies, where it modulates oncogenic signalling, drives epithelial-to-mesenchymal transition (EMT) and enables cell motility. OBJECTIVES: To evaluate CSPG4 expression and function in RDEB cSCC. METHODS: RDEB cSCC cell lines were used to assess CSPG4-dependent changes in invasive potential, transforming growth factor (TGF)-β1-stimulated signal activation and clinically relevant cytopathology metrics in an in vitro full-thickness tumour model. CSPG4 expression in RDEB cSCC and non-RDEB cSCC tumours was analysed via immunohistochemistry and single-cell RNA sequencing (scRNA-Seq), respectively. RESULTS: Inhibiting CSPG4 expression reduced invasive potential in multiple RDEB cSCC cell lines and altered membrane-proximal TGF-β signal activation via changes in SMAD3 phosphorylation. CSPG4 expression was uniformly localized to basal layer keratinocytes in fibrotic RDEB skin and tumour cells at the tumour-stroma interface at the invasive front in RDEB cSCC tumours in vivo. Analysis of published scRNA-Seq data revealed that CSPG4 expression was correlated with an enhanced EMT transcriptomic signature in cells at the tumour-stroma interface of non-RDEB cSCC tumours. Cytopathological metrics, for example nucleus : cell area ratio, were influenced by CSPG4 expression in in vitro tumour models. CONCLUSIONS: We determined that CSPG4 expression in RDEB cSCC cell lines enhanced the invasive potential of tumours. Mechanistically, CSPG4 was found to enhance membrane-proximal TGF-β-stimulated signalling via SMAD3, which is a key mediator of EMT in RDEB cSCC. The implication of these studies is that CSPG4 may represent a therapeutic target that can be leveraged for the clinical management of patients with RDEB cSCC. Recessive dystrophic epidermolysis bullosa (or ‘RDEB’) is a rare skin disease that affects 3 in 1 million children worldwide. People with RDEB lack an essential protein that allows the skin to resist tearing. This results in widespread blistering on the body and chronic wounds. People with RDEB can develop a lethal form of ‘metastatic’ skin cancer (where cancer cells spread to other parts of the body). However, before a cancer becomes metastatic, a cell must ‘invade’ its original tissue for it to access other parts of the body. This USA-based study investigated a protein called ‘CSPG4’. This protein is present on the surfaces of cancer cells but not in most normal tissues. Our aim was to look at whether CSPG4 enhances the invasion of skin cancer associated with RDEB. This mechanism could be targeted by anti-cancer treatments. We used skin cancer cells from people with RDEB to demonstrate that CSPG4 increases the invasive ability of cancer cells. It does this by changing how the cells respond to a signal (called ‘TGF-β’) that is present in high levels in RDEB skin. We used cancer tissue from people with RDEB to show that CSPG4 is produced by cells at the edges of tumours. These cells are responsible for invading the surrounding normal tissue. Our findings suggest that CSPG4 could be a therapeutic target. Targeting this protein may limit the ability of RDEB-associated skin cancer to invade and metastasize.
引用
- Macaulay ARK, Yang J, Price MA, et al. Chondroitin sulfate proteoglycan 4 increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying transforming growth factor-β signalling. Br J Dermatol. 2024. PMID: 39018437. doi:10.1093/bjd/ljae295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。